125 related articles for article (PubMed ID: 989368)
1. Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man.
Hackett AM; Griffiths LA; Luyckx AS; van Cauwenberge H
Arzneimittelforschung; 1976; 26(5):925-8. PubMed ID: 989368
[TBL] [Abstract][Full Text] [Related]
2. The disposition and metabolism of 3',4',7-tri-O-(beta-hydroxyethyl)rutoside and 7-mono-O-(beta-hydroxyethyl)rutoside in the mouse.
Hackett AM; Griffiths LA
Xenobiotica; 1977 Oct; 7(10):641-51. PubMed ID: 910465
[TBL] [Abstract][Full Text] [Related]
3. The metabolism and excretion of 7-mono-0-(beta-hydroxyethyl) rutoside in the dog.
Hackett AM; Griffiths LA
Eur J Drug Metab Pharmacokinet; 1979; 4(4):207-12. PubMed ID: 535600
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
Kienzler JL; Sallin D; Schifflers MH; Ghika A
Eur J Clin Pharmacol; 2002 Sep; 58(6):395-402. PubMed ID: 12242598
[TBL] [Abstract][Full Text] [Related]
5. [Studies in animal experiments on determination of blood and organ levels of o-(beta-hydroxyethyl)-rutosides (HR) after i.p. administration (author's transl)].
Reinartz G; Wurst F
Arzneimittelforschung; 1980; 30(4):657-9. PubMed ID: 7190409
[TBL] [Abstract][Full Text] [Related]
6. The effect of O-(beta-hydroxyethyl)-rutosides (HR) on the skin capillary resistance of rats.
Gábor M
Arzneimittelforschung; 1981; 31(3):442-5. PubMed ID: 7194669
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
8. Hepatic clearance and disposition of hydroxyethylrutosides.
Griffiths LA; Hackett AM
Arch Toxicol Suppl; 1978; (1):243-6. PubMed ID: 277108
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of O-(beta-hydroxyethyl)-rutoside on cis-platinum-induced acute renal failure in the rat.
Dobyan DC; Bull JM; Strebel FR; Sunderland BA; Bulger RE
Lab Invest; 1986 Nov; 55(5):557-63. PubMed ID: 3773477
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
[TBL] [Abstract][Full Text] [Related]
12. The metabolism and excretion of (+)-[14C]cyanidanol-3 in man following oral administration.
Hackett AM; Griffiths LA; Broillet A; Wermeille M
Xenobiotica; 1983 May; 13(5):279-86. PubMed ID: 6636824
[TBL] [Abstract][Full Text] [Related]
13. Route-dependent comparative metabolism of [14C]toluene 2,4-diisocyanate and [14C]toluene 2,4-diamine in Fischer 344 rats.
Timchalk C; Smith FA; Bartels MJ
Toxicol Appl Pharmacol; 1994 Feb; 124(2):181-90. PubMed ID: 8122263
[TBL] [Abstract][Full Text] [Related]
14. [Long-term therapy of retinal vasculopathies with oral administration of high doses of O-(beta-hydroxyethyl)-rutoside].
Agolini G; Cavallini GM
Clin Ter; 1987 Jan; 120(2):101-10. PubMed ID: 2972438
[No Abstract] [Full Text] [Related]
15. [A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].
Nocker W; Diebschlag W; Lehmacher W
Vasa; 1989; 18(3):235-8. PubMed ID: 2678805
[TBL] [Abstract][Full Text] [Related]
16. The effect of HR (O-Beta-Hydroxyethylo-Rutoside, Venoruton) on the deformability of erythrocytes in patients with arteriosclerosis obliterans of lower limbs.
Lukjan H; Rość D; Chyzy R; Bodzenta A; Szpak A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):191-6. PubMed ID: 2581865
[TBL] [Abstract][Full Text] [Related]
17. O-(beta-hydroxyethyl)-rutoside (Venoruton) fails to block histamine or bradykinin-induced edema formation in the canine forelimb perfused at constant arterial inflow.
Dobbins DE; Soika CY; Dabney JM
Microcirc Endothelium Lymphatics; 1984 Oct; 1(5):509-23. PubMed ID: 6546155
[TBL] [Abstract][Full Text] [Related]
18. [HPLC determination of troxerutin in plasma and urine following oral administration in man].
Dittrich P; Ostrowski J; Beubler E; Schraven E; Kukovetz W
Arzneimittelforschung; 1985; 35(4):765-7. PubMed ID: 4015744
[TBL] [Abstract][Full Text] [Related]
19. Effect of Venoruton on the factor XIII activity in rat plasma.
Grochal M; Sempińska-Edelberg E; Plewiński J
Pol J Pharmacol Pharm; 1978; 30(5):659-63. PubMed ID: 751007
[TBL] [Abstract][Full Text] [Related]
20. [Dose-response study with O-(beta-hydroxyethyl)-rutoside oral solution].
Nocker W; Diebschlag W
Vasa; 1987; 16(4):365-9. PubMed ID: 3321740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
